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Introduction
Life expectancy of HIV-positive individuals treated with antiretroviral therapy (ART) in the UK improved by nearly 16 years between 1996 and 2008 [1] . Although some groups of HIV-positive individuals may expect to live a similar life span to that of the general population, others have reduced life expectancy due to the impact of late diagnosis and late initiation of ART [1, 2] . A previous study estimated life expectancies of HIV patients in the UK stratified by CD4
þ cell count at ART start [1] , but not gains in years of life in response to ART [1] . A European study showed that successfully treated patients who attained a CD4 þ cell count more than 500 cells/ml have a standardized mortality ratio (SMR) approaching 1 [3] . However, SMRs are more difficult to communicate to patients than life expectancies and not all patients attain a CD4
þ cell count more than 500 cells/ml [4, 5] . The lower limit of the normal CD4 þ cell count range is below 500 cells/ml, and therefore exceeding this level might be an unrealistic target for patients who had low preinfection counts [6] . Furthermore, viral suppression is an important factor in treatment success [7] and virological replication may have an effect on prognosis that is independent of CD4 þ cell count [8, 9] .
We aimed to investigate the improvement in life expectancy due to CD4 þ cell count restoration and viral suppression in patients on ART. We used data from the UK Collaborative HIV Cohort (UK CHIC) Study, on HIV-positive individuals in care in the UK between 2000 and 2012, to estimate life expectancy of those treated for HIV-infection at different durations of ART according to latest CD4 þ cell count and viral suppression status.
Materials and methods

Cohort description
The UK CHIC Study was initiated in 2001 and collates routine data on HIV-positive individuals aged 16 years or over attending clinical centres in the UK since 1 January 1996 (see appendix) [10] . The project uses anonymized data and was approved by a Multicentre Research Ethics Committee and by local ethics committees.
Patient selection
Patients included in this analysis were aged 20 years and over and started treatment with ART with at least three drugs between 1 January 2000 and 31 December 2010 and were followed up until 31 December 2012. Individuals whose assumed transmission was via injection drug use or mother-to-child were excluded due to low frequencies and worse prognosis compared with other risk groups. Patients with missing baseline CD4 þ cell count were included in the study population. Patients were followed up from ART start for all-cause mortality.
Deaths were ascertained from clinic records and by linkage to national surveillance data that use the UK civil death registry. Patients were considered lost to follow-up if they did not have a visit date within 2 years of database close date and were not known to have died before 31 December 2012. Those lost to follow-up were censored at the date of the last visit plus 3 months. Crude rate of losses to follow-up was determined and characteristics of patients who were and were not lost to follow-up were compared.
Variable measurements
The latest CD4 þ cell count before starting ART and the last measured in the first, second, third, fourth and fifth year of ART were determined for patients remaining in follow-up. We determined whether patients were virally suppressed (HIV-1 RNA <400 copies/ml) in the previous year for those remaining under follow-up. For the first year of ART, we used measurements of viral load from 6 to 12 months duration of ART.
Statistical methods
Crude sex-specific mortality rates (per 1000 personyears) were calculated overall and for those aged 20-44 years. Six Poisson models were used to estimate mortality rates from start of ART and for each duration of ART (follow-up starting at 0, 1, 2, 3, 4 and 5 years after ART start), by sex, age, latest CD4 þ cell count (<200, 200-349, 350 cells/ml) and viral load (400 versus >400 copies/ml). Abridged life tables were constructed for each sex from age-specific mortality rates grouped in 5-year age bands and used to estimate life expectancy for ages 20-85 years. These tables describe the mortality experience that hypothetical cohorts of HIV-positive individuals would have if they were subjected to the mortality in the observed period. Life expectancy at an exact age is defined as the average number of years remaining among individuals who survived to the specified age, according to the cross-sectional age-specific all-cause mortality rates during the study period. In this article, we present expected age at death instead of life expectancy, as clinicians and patients have indicated a preference for this. For example, if a 35-year-old has a life expectancy of 40 years, their expected age at death would be 75 years old. The main analyses estimated expected age at death [95% confidence interval (95% CI)] for each sex overall, and stratified by both achieved CD4 þ cell count and viral suppression status at exact ages 20, 35 and 50 years old. Secondary analyses estimated the effect on expected age at death of attained CD4 þ cell count unadjusted for viral suppression and vice versa.
We used sex-specific mortality rates in the UK population for 2000-2009 grouped in 5-year age bands to estimate life expectancies of the general population (www.morta lity.org). Life expectancies were compared for those with attained CD4 þ cell count 350-499 versus at least 500 cells/ml. Detailed information on the calculation of
Results
The UK CHIC Study included data on 47 201 HIVpositive individuals of whom 22 151 started ART between 2000 and 2010. We excluded 568 (3%) IDU, 164 (0.7%) infected via mother-to-child transmission, two patients without sex recorded and 29 aged less than 20 years, which left 21 388 eligible patients. Table 1 summarizes the demographic and clinical characteristics of patients at ART start by sex and the proportion of patients with missing data for each covariate. The majority of patients 14 742/21 388 (69%) were men, and of these, 10 246 (71%) were MSM, and 9649 (67%) were of white ethnicity. In contrast, nearly all the women 6265/6646 (97%) were infected heterosexually and the majority 4778 (74%) were black African. The women were younger than the men with very few aged 60 years or more.
During 110 697 person-years, 961/21 388 (4.5%) patients died. The crude mortality rate of 9.0 per 1000 personyears for men (95% CI 8.4-9.7) was higher than rate of 7.9 for women (7.0-8.9), but was the same in both sexes for those aged less than 45 years [men 6.9 (6.2-7.7); women 6.9 (6.0-7.9)]. Rate of losses to follow-up was 3.9 per 100 person-years. Compared with those retained in care, patients lost to follow-up were more likely to be men, infected through heterosexual contact or blood (or unknown), black African, Asian or mixed race (or unknown), younger, diagnosed with AIDS prior to starting ART and had higher CD4
þ cell count at ART start, although median CD4 
Effect of CD4
R cell count and viral suppression on life expectancies Expected age at death (95% CI) for men ( Table 2 ) and women (Table 3) showed a graded association with both attained CD4
þ cell count and viral suppression status. At ART start, a 35 year-old man with CD4 þ cell count less than 200 cells/ml could expect to live to 71 (68-73) years, over 7 years less than men in the general UK population. Such a patient who achieved viral suppression and increased their CD4 þ cell count in the first year of ART to 200-349 or at least 350 cells/ml increased their expected age at death to 78 (74-82) or 81 (77-84) years, respectively. This is comparable with the general population male life expectancy of 78 years. After 5 years on ART, expected age at death of 35-year-old men varied from 54 (48-61) to 80 (76-83) years for those with CD4 þ cell count less than 200 cells/ml and no viral suppression versus CD4
þ cell count at least 350 cells/ml and suppressed. Figures 1 (men) and 2 (women) illustrate that within each CD4 þ cell count strata, expected age at death is higher for those with than those without viral suppression.
Compared with men at ART start, the expected age at death was between 3 and 4 years greater for those who survived 5 years on ART (Table 2) , depending on their current age. Life expectancy was higher for women reflecting the higher life expectancy of women in the general population (Table 3 ). There was no difference in mortality between those with CD4 þ cell count 350-499 and at least 500 cells/ml for either men or women.
Median CD4
þ cell count increased with duration of ART and was higher in those with viral suppression (Supplementary figure 1, http://links.lww.com/QAD/ A495). The proportion of patients with CD4
þ cell count at least 350 cells/ml increased markedly in the first year of ART, and continued to increase up to 5 years on ART (Supplementary figure 2, http://links.lww.com/QAD/ A495). Only 19% of patients had CD4
þ cell count more than 350 cells/ml at ART start, compared with 79% of patients on ART for more than 5 years, with 52% having CD4 þ cell count more than 500 cells/ml. Life expectancy and response to antiretroviral therapy May et al. 1197 Table 2 . Expected age at death (95% confidence interval) of men stratified by viral suppression and attained CD4 R cell count at 1, 2, 3, 4 and 5 years after start of antiretroviral therapy.
HIV-1 RNA (copies/ml) 400
HIV-1 RNA (copies/ml) >400 68 (66-71) Table 3 . Expected age at death (95% confidence interval) of women stratified by viral suppression and attained CD4
R cell count at 1, 2, 3, 4 and 5 years after start of antiretroviral therapy.
HIV-1 RNA (copies/ml) >400 with duration of ART. Although most of the effect of viral suppression on decreasing mortality is likely to be mediated through increasing CD4 þ cell count, nevertheless there remained an independent effect of detectable viral load on life expectancy. Those with CD4 þ cell count less than 200 cells/ml at 5 years after starting ART lost between 15 and 26 potential years of life depending on whether they were or were not virally suppressed.
Strengths and limitations of study
We analysed data on over 20 000 patients on ART, among whom there were nearly a thousand deaths. Our study was based on a cohort that included approximately 34% of patients in usual care for HIV infection in UK and therefore our estimates of expected age at death should be applicable to patients on ART in the UK. In 2012-2013, UK CHIC undertook extensive linkage with databases held at Public Health England (PHE) in order to validate the reporting of deaths by the participating hospital clinics and to include deaths missing from HIV clinic records (approximately 16% of all deaths), which were reported in the UK civil death register. Therefore completeness of death ascertainment should be high [11] . However, as many patients were lost to follow-up, there remains the possibility of missed deaths, which would bias estimates of expected age at death upwards. As expected, patients lost to follow-up were more likely to have characteristics associated with migrant backgrounds and some may have returned to their country of origin now that ART is more widely available, particularly in sub-Saharan Africa. Analyses of those lost to follow-up were inconclusive in determining whether lost patients were likely to have lower or higher mortality than those remaining in care. Reasons for losses to follow-up are varied and as well as including dropping out of care and deportation, also include transferring care to another ART provider, either in the UK, but not contributing to UK CHIC, or abroad. Although there was some evidence that, compared with those who remained in the study, those who dropped out were sicker (positive association with AIDS diagnosis), other associations implied that a well group were also lost to follow-up (younger and having a higher CD4 þ cell count). As in a French study [12] , men were more likely to be lost than women, which could be because men are a more mobile population. In each time period considered, only patients with data on CD4 þ cell count and viral load measurements could be included, which led to around 10% of patients being excluded from each model. Therefore, our results may only apply to patients remaining in regular care in the UK, but this will be the majority of HIV-positive individuals in the continuum of care [13] . Our estimates of life expectancy only used age and sex-adjusted estimates of mortality rates that were stratified by response to ART determined by attained CD4 þ cell count and viral suppression status. A greater range of variables, including non-HIV biomarkers, have been used in prognostic models that aim to define short-term prognosis rather cancy [7, [14] [15] [16] [17] .
Estimated life expectancy may be biased by extrapolation beyond available data. There were few patients aged more than 60 years (<3% of the total) and therefore estimates of mortality rates at older ages are imprecise, particularly in women. We compensated for this by using Poisson regression models to estimate mortality rates, which borrowed strength from trends across age and sex. Thus, we ensured that the rates used in lifetables were smoother than crude sex and age-specific rates would have been. However, this also constrained mortality patterns to be similar for men and women, which may not be true. In using lifetables, we are assuming that age-specific mortality rates estimated from the current population can be used as if they will apply within individuals throughout their lives. However, these estimates are based on a population that has experienced a maximum duration of ART of 12 years, whereas a current patient who starts ART at age 35 years will, for example, when they are aged 60 experience the mortality rates of a 60 year-old conditional on having taken ART for 25 years. Possible scenarios that have been considered in a modelling exercise are that there will be long-term toxic effects of ART or that patients will run out of treatment options due to drug resistance [18] . On the contrary, in the future, better ART drugs may be developed or less toxic combinations used. In particular, NRTI-sparing regimens may reduce long-term toxicities. Currently, there is considerable interest and ongoing trials in ART simplification strategies [19] , such as using a single boosted protease inhibitor as a maintenance regimen in those who are stable and virologically suppressed on ART [20] , which will also reduce the cost of lifelong ART.
Discussion of findings in context
In response to the Health and Social Care Act 2012 [21] , PHE has implemented a new scheme for monitoring the success of ART, which assesses both the proportion of patients with viral suppression and the proportion with CD4
þ cell count at least 350 cells/ml; our study shows that both are associated with mortality risk and lost years of life. Although better immunological function is critical for avoiding AIDS-related mortality and may be important for avoiding some non-AIDS cancers [22] [23] [24] , the inflammatory effect of viral replication may be also be associated with excess mortality, and in particular the SMART study showed an increased risk from cardiovascular disease with higher levels of interleukin-6, C-reactive protein and D-dimer [25] . Mendelian randomization studies suggest that interleukin-6 [26] , but not C-reactive protein [27] , is causally associated with coronary heart disease in the general population. Further research is required to establish whether any of the associations of these biomarkers of inflammation with mortality are causal in HIV-infected populations.
During the study period, guidelines recommended starting ART once CD4 þ cell count had fallen below 350 cells/ml unless treatment was required for prevention of mother-to-child transmission or in the case of an AIDS diagnosis or other particular health need [28] . This explains the paradoxical finding that life expectancy from ART start was lower in those who started with CD4 þ cell count at least 350 compared with 200-349 cells/ml; they would have been a highly selected group. However, with the move towards treatment as prevention [29] and the change in WHO guidelines to starting at CD4 þ cell count below 500 cells/ml [30] , it is likely that more people in the UK will start ART at higher CD4 þ cell count even if asymptomatic. The current 2012 British HIV Association guidelines [31] continue to recommend that ART is started once CD4 þ cell count has fallen below 350 cells/ml but allow for treatment above this threshold to reduce the risk of transmission to partners if the patient wishes to start ART.
The predicted longevity is dependent on successfully navigating the continuum of care, which requires diagnosis of HIV infection before severe immunosuppression, prompt linkage to care, timely initiation of treatment, good adherence to ART and retention in care [1, 32] . Although at later durations of ART, attained is more important than nadir CD4 þ cell count, it is important to realize that estimated life expectancies are conditional on surviving the first year of ART and this is highly dependent on nadir CD4 þ cell count [14] . Furthermore, our analysis does not include individuals who never start ART, which will exclude some individuals with the poorest prognosis. Our study supports a previous analysis which showed that patients successfully treated with ART should be eligible for life insurance at affordable premiums [33] .
Our study is observational, and therefore associations of CD4 þ cell count and viral suppression with differences in life expectancy may not be causal. We have not examined whether patients have stopped ART, are poorly adherent or have other risk factors for higher mortality. Failure to attain an adequate CD4 þ cell count or suppressed viral load may be due to failure of the ART regimen and resistance developing, or due to patients being unable or unwilling to take the treatment [34] , but it could also be associated with other lifestyle, behavioural or clinical factors that lead to a higher underlying mortality. HIVpositive populations generally have a higher prevalence of smoking [35] , alcohol [36] and illicit drug abuse [37, 38] , and hepatitis B and C coinfection, which are risk factors for mortality and may be associated with lower attained CD4 þ cell count and higher viral load [39] [40] [41] . Nevertheless, our results indicate that those with CD4 þ cell count at least 350 cells/ml and suppressed viral load have a life expectancy slightly higher than the general population. This could be due to missing deaths or it could be real, as this population is in clinical care and frequently monitored and therefore might receive better management of chronic disease risk factors and earlier diagnosis of other diseases, such as cancer, compared with the general population. In a combined analysis of well controlled HIV-infected adults in the SMART and ESPRIT clinical trials in which ascertainment of death should be less affected by losses to follow-up, SMR estimates for patients with viral suppression and CD4 þ cell count at least 350 cells/ml varied between 1 (0.73-1.34) and 1.57 (1.26-1.94) depending on the criteria used for including follow-up time [9] . SMR estimates were higher for CD4 þ cell count between 350 and 499 compared with at least 500 cells/ml, but CIs overlapped [9] . In our study of patients in usual clinical care, we found no strong evidence of differences in mortality rates between these CD4 þ cell count categories and therefore did not estimate life expectancy separately.
